TGPHF - Together Pharma Ltd

Other OTC - Other OTC Delayed Price. Currency in USD

0.0900

0.0000

(0.00%)

At close: 01:07PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	0.0900
Open	0.0900
Bid	N/A x N/A
Ask	N/A x N/A
Day's Range	0.0900 - 0.0900
52 Week Range	0.0900 - 0.0900
Volume	456
Avg. Volume	0

Market Cap	7.907M
Beta (5Y Monthly)	0.38
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TGPHF

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

PR Newswire
Cantourage, Cannabis House and Together Pharma partner to increase availability of medical cannabis in Poland
Cantourage Group SE (FRA: HIGH), a European medical cannabis leader, Cannabis House, an initiative enabling the distribution of medical cannabis in Poland, and Together Pharma (TASE: TGTR), an Israeli producer of medical cannabis, today announced a partnership that makes Ugandan medical cannabis available in Poland for the first time. From the first week of December, Polish patients enrolled in the Cannabis House initiative will have access to Together Pharma's Glueberry OG® cultivar, which will
GlobeNewswire
494% Increase in Assets to US$33 million Israeli Cannabis Technology Company BYND Cannasoft Enterprises Inc. Poised for Growth
Strengthened balance sheet, increased gross margins, and reduced expenses provide increased focus on growth based on BYND Cannasoft’s CRM SaaS platform, medical cannabis, and EZ-G deviceASHKELON, Israel and VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today future plans for growth after posting a 494% increase in assets for the nine-month period ended September 30, 2022. The
GlobeNewswire
Tel Aviv Listed Together Pharma’s Subsidiary Globus Pharma Ltd and BYND Cannasoft Enterprises’ Subsidiary Sign First Commercial Agreement for Medical Cannabis Products
VANCOUVER, British Columbia and ASHKELON, Israel, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today its Israeli subsidiary signed an agreement with Globus Pharma LTD, a subsidiary of Israeli-based Together Pharma Ltd (TA: TGTR), for the cultivation, production, and distribution of medical cannabis products that are expected to generate significant revenues for the company before costs of manufacturing

TGPHF - Together Pharma Ltd

Chart Events

Performance Outlook

Fair Value

Related Research

Cantourage, Cannabis House and Together Pharma partner to increase availability of medical cannabis in Poland

494% Increase in Assets to US$33 million Israeli Cannabis Technology Company BYND Cannasoft Enterprises Inc. Poised for Growth

Tel Aviv Listed Together Pharma’s Subsidiary Globus Pharma Ltd and BYND Cannasoft Enterprises’ Subsidiary Sign First Commercial Agreement for Medical Cannabis Products